ATC Group: J05AP07 Daclatasvir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AP07 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AP Antivirals for treatment of HCV infections
5 J05AP07

Active ingredients in J05AP07

Active Ingredient Description
Daclatasvir

Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.

Medicines in this ATC group

Brazil (BR)

Estonia (EE)

Hong Kong (HK)

Lithuania (LT)

Nigeria (NG)

Poland (PL)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.